Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Cancer Res. 2010 Nov 2;70(22):9185–9196. doi: 10.1158/0008-5472.CAN-10-1545

Figure 1. The Casp9a/9b mRNA ratio is dysregulated in NSCLC tumors and transformed lung epithelial cells.

Figure 1

cDNAs from pathologist-verified lung adeno-, squamous, and large cell carcinomas (Origene) underwent quantitative/competitive PCR for expression of Casp9 splice variants. A) Representation of matched pair analysis used for the degree of Casp9a/9b dysregulation in NSCLC tumors. N= normal, T=tumor. B) RT-PCR analysis of Casp9 splice variants showing 36% of NSCLC tumors are moderately dysregulated (C9a/9b ratio of 2.2–3.3) and 42% of NSCLC tumors are highly dysregulated (C9a/9b ratio <2.2) (N=149). C) RT-PCR analysis of Casp9 splice variants from NSCLC and HBEC-3KT cells. The “*” indicates a dysregulated Casp9a/9b mRNA ratio and “**” indicates a moderately dysregulated Casp9a/9b mRNA ratio. D) In parallel, protein expression of Casp9 splice variants.